Drug Trial Radar · NCT06271252
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Last checked: Nov 19, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
81
Planned (sponsor's estimate)
Start
Apr 3, 2024
Primary completion
Dec 12, 2026
Study completion Apr 12, 2028
Sponsor
- Lead sponsor
- OriCell Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study
Conditions
- Neoplasms, Plasma Cell
- Neoplasms by Histologic Type
- Neoplasms
- Hemostatic Disorders
- Vascular Diseases
- Cardiovascular Diseases
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Immune System Diseases
- Multiple Myeloma
Interventions
OriCAR-017Drug
Anti-GPRC5D CAR-T cell product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of OriCAR-017 US-P1Time frame: Up to 28 days
- Dose-limiting toxicity (DLT)Time frame: Up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northside Hospital
Atlanta, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.